What is Alembic?
Alembic operates as a specialized pharmaceutical entity focused on the development and distribution of high-quality generic medications. The company has recently expanded its portfolio with the introduction of lacosamide tablets, a generic alternative to UCB's Vimpat, available in multiple dosage strengths ranging from 50 mg to 200 mg. This product is strategically indicated for the treatment of partial-onset seizures in patients as young as one month old. By providing accessible, cost-effective therapeutic options, Alembic reinforces its market position as a critical supplier in the pediatric and adult neurology space, ensuring that essential seizure management treatments are readily available in 60-count distribution formats.
How much funding has Alembic raised?
Alembic has raised a total of $70K across 1 funding round:
Debt
$70K
Debt (2021): $70K with participation from PPP
Key Investors in Alembic
PPP
Public-Private Partnership
What's next for Alembic?
With this recent infusion of capital, Alembic is poised to accelerate its operational footprint and enhance its supply chain resilience. The firm is expected to leverage these resources to optimize its manufacturing processes and potentially broaden its pipeline of generic neurological treatments. As the company navigates the competitive landscape of generic pharmaceuticals, the focus will likely remain on regulatory compliance, market penetration of its lacosamide line, and the strategic scaling of its distribution network to meet the growing demand for affordable seizure management solutions. This growth trajectory suggests a robust outlook for the company as it continues to challenge established incumbents through high-volume, high-quality generic production.
See full Alembic company page
